Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and Vorinostat with GemBuMel Conditioning for SCT in Refractory Lymphomas
NCT01983969Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2013
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in lymphoma, sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2013; status: completed.
02
Drugs
azacitidine
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT01983969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01983969.